Amplia Therapeutics Resumes ACCENT Trial Enrollment for Pancreatic Cancer
核心洞察
Amplia Therapeutics (搜索) has restarted recruitment for the final cohort of patients in its Phase 2a ACCENT trial, evaluating a novel treatment for pancreatic cancer (搜索).
The ACCENT trial aims to enroll a total of 50 patients, with the final cohort consisting of 24 participants across sites in Australia and South Korea.
Recruitment for the trial is expected to be completed by the end of Q1 2025, with the Calvary Mater Hospital in Newcastle recently becoming an active trial site.
Amplia Therapeutics (搜索) has announced the resumption of recruitment for the final cohort of patients in the Phase 2a ACCENT clinical trial, which is evaluating a novel therapeutic approach for pancreatic cancer (搜索). The first patient in this cohort began treatment this week.
The ACCENT trial aims to enroll a total of 50 patients. The recruitment of the remaining 24 patients is now underway at existing trial sites in Australia and South Korea. This includes the Calvary Mater Hospital in Newcastle, which was recently activated as a trial site. Amplia anticipates completing recruitment by the end of the first quarter of 2025.
Trial Expansion and Leadership Commentary
Dr. Chris Burns, CEO and Managing Director of Amplia, stated, "We are very pleased to begin recruitment of the remaining 24 patients for the ACCENT trial. We plan to complete recruitment by the end of March 2025, and to increase the opportunities for patients to join the trial we have this week also opened recruitment at the Calvary Mater Hospital in Newcastle."